Response assessment in mRCC: RECIST or DWI? · 2013. 12. 3. · • 30% have metastatic disease at...
Transcript of Response assessment in mRCC: RECIST or DWI? · 2013. 12. 3. · • 30% have metastatic disease at...
RESPONSE ASSESSMENT IN METASTATIC RCC: RECIST OR DWI?
Andrea G Rockall, MRCP, FRCR Imperial College London
Why is this important?
• In patients with RCC • 30% have metastatic disease at presentation • 30% with confined disease eventually develop
metastases
• Metastatic RCC (mRCC) is now treated with molecular targeted agents
Ratain, JCO 2006, Motzer, NEJM 2007, Motzer, JCO 2007, Hudes, NEJM 2007, Escudier, Lancet 2007
Mutations in VHL (suppressor) gene
Up-regulation of receptor and intracellular tyrosine kinase (TK)
TK inhibitors (TKIs)
Sunitinib Pazopanib Sorafenib
(axitinib and tivozanib)
mTOR inhibitors
Bevacizumab
VEGF/PDGF Tumor proliferation and
angiogenesis
Anti-angiogenic Anti-proliferative
Cytostatic
Why is this important?
• No benefit if ‘non-responders’ continue therapy – Side-effects – Costly
• Despite non-response to one TKI, there may be response to another TKI*
• Can we identify non-responders early? • If so, which is the best technique?
*Rini et al, JCO, 2009
What criteria do you use to report response to targeted
agents in mRCC?
A. RECIST (either 1.0 or 1.1) B. Modified RECIST or SACT C. MRI with DWI and/or DCE D. Arterial spin labelling E. FDG-PET/CT
Limitations of anatomic morphologic imaging
� Residual mass may not be biologically active
� Limited change in tumor size may not correlate with patient
outcome with targeted chemotherapy
Pre
Sunitinib Post
Sunitinib
Can RECIST criteria predict response?
� RECIST criteria had sensitivity of 16% for predicting favorable PFS (Smith et al, AJR ‘10)
� Response rates by RECIST did not predict survival
� Sunitinib 31% (Motzer et al, NEJM 2007)
� Sorafenib 10% (Escudier et al, NEJM, 2007)
� Sunitinib or cediranib 25% (Nathan et al, CBT, 2010)
Functional imaging
� Imaging that reflects the physiological milieu of the tumour e.g. � Vascularity of the tumour � Diffusivity of water within the tumour � Cell metabolism or cell wall turnover
� Qualitative as well as quantitative evaluations can be made
� Characterise the tumour – to predict behaviour and measure response
Effect of targeted agent on tumor
CT correlate MRI correlate
Decrease in vascularity
Necrosis
Moderate decrease in size
Baccala Ajr et al, Int J Urol 2007
Decrease in enhancement (ktrans, Kep, Ve)
Decrease in attenuation (HU)
Increase in water diffusivity (ADC)
Decrease in attenuation (HU)
Reduction in size (RECIST)
Reduction in size (RECIST)
GIST: Evaluation of response to imatinib
Choi H, Oncologist, 2008
Modified RECIST: Tumour density decrease of > 15%
OR Tumour size decrease of >10%
Criteria evaluated in mRCC
� Retrospective analysis � RECIST � Modified RECIST (Choi) � Modified Choi* � Mean volumetric tumor attenuation (non-lung
target lesions)
� Correlated with time to progression and disease-specific survival
Smith AD et al, AJR 2010 *Nathan PD et al, CBT, 2010
Response status
% of patients showing change in SIZE
> 30% decrease in size
> 20% decrease in size
> 10% decrease in size
> 20% increase in size
PFS > 250 days 16 39 70 2
PFS <250 days 0 0 22 22
Response status % of patients showing change in ATTENUATION
1 or more lesion decreases by > 40HU
At least half of lesions decrease by > 20HU
PFS > 250 days 59 68
PFS < 250 days 0 0
Response Size and Attenuation CT (SACT) Criteria
Favorable No new lesion and any of the following: 1. Decreased in tumor size of > 20% 2. Decrease in size of > 10% and > 20HU mean attenuation* 3. One or more lesions with > 40 HU decrease in attenuation*
Indeterminate Does not fit criteria for favorable or unfavorable
Unfavorable Any of the following: 1. Increase in tumor size of > 20% 2. New met, marked central fill-in of target lesion or new
enhancement of previously hypoattenuating non-enhancing lesion
Smith AD et al, AJR 2010 * Non lung target lesion
What about sequential FDG-PET/CT?
� In 44 patients, high SUVmax and increased number of PET + lesions correlated with inferior survival
� Decrease in SUVmax >20% at 4 wks did not correlate with PFS or OS
� Metabolic progression at 16wks predicted inferior survival
Kayani,...Rockall.. et al, Clin Can Res, 2011
What if patient is in renal failure?
� Can DWI / change in ADC predict response? � Up to a third of patients are unable to have contrast
� Change in ADC has been reported to predict response in: � Cervix cancer � Rectal cancer � Hepatocellular carcinoma
Nathan et al, CBiol &Ther 2010; Harry V et al, GynOncol 2008 Dzik-Jurasz A et al, Lancet, 2002; Kamel IR et al, JVIR 2006
Pre Sunitinib
Post Sunitinib
Change in ADC? Necrosis?
Early response?
DW-MRI pre and post sunitinib
* = involved lymph nodes; LK = left kidney
Right Renal Cell Carcinoma
Whole tumor pixel-by-pixel ADC histograms before and after three cycles of sunitinib
Bharwani N , Miquel M....Rockall ISMRM, RSNA 2011
0
1
2
3
4
5
6
7
850 20
0
350
500
650
800
950
1100
1250
1400
1550
1700
1850
2000
2150
2300
2450
2600
2750
2900
3050
3200
3350
3500
Visit 1
Visit 2
Responder?
Bharwani N , Miquel M....Rockall ISMRM, RSNA 2011
No. of pixels
ADC
0
1
2
3
4
5
6
7
50 150
250
350
450
550
650
750
850
950
1050
1150
1250
1350
1450
1550
1650
1750
1850
1950
2050
2150
2250
2350
2450
2550
2650
2750
2850
2950
Visit 1
Visit 2
Non-responder?
Bharwani N , Miquel M....Rockall ISMRM, RSNA 2011
No. of pixels
ADC
Histogram Analysis
Mean ADC values of the entire tumor volume
The area of the histogram in the 1st quartile of the x-axis (AUC25) was correlated with outcome
AUC25
P=.038
0.00
0.25
0.50
0.75
1.00
0 3 6 9 12 15 18 21 24 27 30 33 36Months
Decrease in AUC > median Decrease in AUC25 < median
OS by %decrease in AUC25
Overall survival correlates with a decrease in AUC25
Decrease in ‘restricted’ pixels post Rx
Conclusions
� RECIST criteria are not adequate for assessing response in patients mRCC on targeted agents (SD may represent response)
� Size and attenuation CT (SACT) criteria are the ‘front runner’
� In patients unable to have contrast media, diffusion weighted imaging is a promising alternative